Finally, PF-06817024 is one of the most recent anti-IL-33 monoclonal antibodies developed by Pfizer; a phase I placebo-controlled trial in healthy subjects, patients with chronic nasal sinusitis and patients with AD was completed in 2022, with no evidence of serious adverse events (NCT02743871) [180]. The gene discussed is IL33; the disease is Alzheimer disease.